PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34411648-0 2021 ABCB1 c.3435C>T and EPHX1 c.416A>G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients. Carbamazepine 66-79 ATP binding cassette subfamily B member 1 Homo sapiens 0-5 15371980-0 2004 Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Carbamazepine 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 35-49 15371980-10 2004 CONCLUSIONS: Aside from induction of CYP3A4, carbamazepine acts as an inducer of intestinal MDR1 mRNA, MRP2 mRNA, and MRP2 protein content. Carbamazepine 45-58 ATP binding cassette subfamily B member 1 Homo sapiens 92-96 12954800-7 2003 In the calcein assay only carbamazepine inhibited Pgp, which was confirmed in confocal laser-scanning microscopy. Carbamazepine 26-39 ATP binding cassette subfamily B member 1 Homo sapiens 50-53 11318771-1 2001 AIMS: To determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). Carbamazepine 46-59 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 11318771-1 2001 AIMS: To determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). Carbamazepine 46-59 ATP binding cassette subfamily B member 1 Homo sapiens 166-169 11318771-1 2001 AIMS: To determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). Carbamazepine 61-64 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 11318771-1 2001 AIMS: To determine whether the anticonvulsant carbamazepine (CBZ), a known CYP3A4 substrate, is also a substrate for the multidrug efflux transporter P-glycoprotein (Pgp). Carbamazepine 61-64 ATP binding cassette subfamily B member 1 Homo sapiens 166-169 11318771-8 2001 Furthermore, the interaction of CBZ with drugs that modulate both CYP3A4 and Pgp function such as verapamil is probably due to inhibition of CYP3A4 and not Pgp. Carbamazepine 32-35 ATP binding cassette subfamily B member 1 Homo sapiens 77-80 11733711-0 2001 P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Carbamazepine 146-159 ATP binding cassette subfamily B member 1 Homo sapiens 0-14 11733711-8 2001 The data indicate that both PGP and MRP participate in the regulation of extracellular brain concentrations of the major AED carbamazepine. Carbamazepine 125-138 ATP binding cassette subfamily B member 1 Homo sapiens 28-31 34411648-1 2021 The gene polymorphisms of ABCB1, EPHX1, and SCN1A were found to influence carbamazepine (CBZ) metabolism and resistance in epilepsy patients, but the relevance remains controversial. Carbamazepine 74-87 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 34411648-1 2021 The gene polymorphisms of ABCB1, EPHX1, and SCN1A were found to influence carbamazepine (CBZ) metabolism and resistance in epilepsy patients, but the relevance remains controversial. Carbamazepine 89-92 ATP binding cassette subfamily B member 1 Homo sapiens 26-31 34411648-2 2021 To reveal the relationships among the gene polymorphisms of ABCB1, EPHX1, SCN1A and the metabolism and resistance of CBZ, the databases of PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Science and Technique Journals, China Biology medicine disc and Wan Fang were retrieved for suitable studies up to April 2021. Carbamazepine 117-120 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 34411648-5 2021 Furthermore, ABCB1 c.3435C>T polymorphism was also observed to be significantly influenced CBZ resistance (CC vs TT, OR = 1.78 (95% CI: 1.17~2.72), P = 0.008; CT vs TT, OR = 1.60 (95% CI: 1.12~2.30), P = 0.01; CC+CT vs TT, OR = 1.61 (95% CI: 1.15~2.26), P = 0.006, respectively). Carbamazepine 91-94 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 34411648-6 2021 Therefore, CBZ metabolism and resistance inpatientswithepilepsy may be adjusted by the gene polymorphisms of ABCB1 c.3435C>T and EPHX1 c.416A>G which provides the further scientific basis for clinical individualized therapy of epilepsy. Carbamazepine 11-14 ATP binding cassette subfamily B member 1 Homo sapiens 109-114 34653781-0 2021 Association of ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A meta-analysis. Carbamazepine 40-53 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 34653781-1 2021 OBJECTIVE: ABCB1 polymorphisms were previously demonstrated to be associated with the metabolism and resistance of carbamazepine (CBZ) in epilepsy, but the results still remained controversial. Carbamazepine 115-128 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 34653781-1 2021 OBJECTIVE: ABCB1 polymorphisms were previously demonstrated to be associated with the metabolism and resistance of carbamazepine (CBZ) in epilepsy, but the results still remained controversial. Carbamazepine 130-133 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 34653781-2 2021 Therefore, we performed this meta-analysis to further evaluate the impacts of ABCB1 polymorphisms on CBZ metabolism and resistance. Carbamazepine 101-104 ATP binding cassette subfamily B member 1 Homo sapiens 78-83 34653781-10 2021 CONCLUSIONS: ABCB1 rs1045642 and rs2032582 polymorphisms were associated with CBZ metabolism for epilepsy, and rs1128503 was related to CBZ resistance. Carbamazepine 78-81 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 34653781-10 2021 CONCLUSIONS: ABCB1 rs1045642 and rs2032582 polymorphisms were associated with CBZ metabolism for epilepsy, and rs1128503 was related to CBZ resistance. Carbamazepine 136-139 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 28961159-4 2017 phenytoin, carbamazepine, valproate, lamotrigine, topiramate and levetiracetam, on the expression and function of ABCB1, ABCC1, ABCC2 and ABCG2 in Caco2 and HepG2 cell lines through real time PCR, western blot and functional activity assays. Carbamazepine 11-24 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 31361500-5 2019 Carbamazepine induced the mRNA expressions of CAR, ABCB1, and ABCC2 but did not elevate protein abundance. Carbamazepine 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 51-56 29040230-6 2017 Dose-adjusted serum concentrations were 33% higher in patients 65 years or older and more than 50% lower in patients taking the p-glycoprotein inducer carbamazepine. Carbamazepine 151-164 ATP binding cassette subfamily B member 1 Homo sapiens 128-142 35526327-10 2022 The B. subtilis not only downregulated the expression level and the efflux activity of ABCB1 in Caco-2 cells treated with ASMs (P < 0.01), but also reduced the carbamazepine efflux in the Caco-2 cells (P < 0.05). Carbamazepine 160-173 ATP binding cassette subfamily B member 1 Homo sapiens 87-92 33534133-3 2021 CASE SUMMARY: This case describes suspected P-glycoprotein (P-gp) deinduction by carbamazepine resulting in a slow viral response during treatment of chronic hepatitis C virus (HCV) infection. Carbamazepine 81-94 ATP binding cassette subfamily B member 1 Homo sapiens 44-58 33534133-3 2021 CASE SUMMARY: This case describes suspected P-glycoprotein (P-gp) deinduction by carbamazepine resulting in a slow viral response during treatment of chronic hepatitis C virus (HCV) infection. Carbamazepine 81-94 ATP binding cassette subfamily B member 1 Homo sapiens 60-64 31361500-0 2019 Transcriptional and Post-Transcriptional Regulation of Duodenal P-Glycoprotein and MRP2 in Healthy Human Subjects after Chronic Treatment with Rifampin and Carbamazepine. Carbamazepine 156-169 ATP binding cassette subfamily B member 1 Homo sapiens 64-78 28961159-6 2017 Carbamazepine caused a significant induction in expression of ABCB1 and ABCC2 in HepG2 and Caco2 cells, both at the transcript and protein level, together with increased functional activity. Carbamazepine 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 62-67 26555147-2 2015 MATERIALS & METHODS: Five SNPs in two candidate genes influencing CBZ transport and metabolism, namely ABCB1 or EPHX1, and CBZ response SCN1A (sodium channel) were genotyped in 145 epileptic patients treated with CBZ as monotherapy and 100 age and sex matched healthy controls. Carbamazepine 70-73 ATP binding cassette subfamily B member 1 Homo sapiens 107-112 27450623-6 2016 Carbamazepine, levetiracetam, phenobarbital, phenytoin and valproic acid might decrease the effect of NOACs by inducing P-glycoprotein (P-gp) activity. Carbamazepine 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 27450623-6 2016 Carbamazepine, levetiracetam, phenobarbital, phenytoin and valproic acid might decrease the effect of NOACs by inducing P-glycoprotein (P-gp) activity. Carbamazepine 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 26421491-8 2015 CONCLUSIONS: rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB. Carbamazepine 176-179 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 26421491-8 2015 CONCLUSIONS: rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB. Carbamazepine 176-179 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 26421491-0 2015 Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Carbamazepine 55-68 ATP binding cassette subfamily B member 1 Homo sapiens 24-29 26421491-8 2015 CONCLUSIONS: rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB. Carbamazepine 176-179 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 26421491-8 2015 CONCLUSIONS: rs776746 and rs15524 in the CYP3A5 gene tend to affect CBZ metabolism, and rs2032582, rs10234411 in the ABCB1 gene may contribute to inter-individual variation in CBZ and in CBZ-E transport among patients with epilepsy using CBZ in combination with PHT or PB. Carbamazepine 68-71 ATP binding cassette subfamily B member 1 Homo sapiens 117-122 24861996-0 2014 Association of ABCB1, CYP3A4, EPHX1, FAS, SCN1A, MICA, and BAG6 polymorphisms with the risk of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Chinese Han patients with epilepsy. Carbamazepine 95-108 ATP binding cassette subfamily B member 1 Homo sapiens 15-20 26009790-1 2015 WHAT IS KNOWN AND OBJECTIVE: Carbamazepine is a potent inducer of cytochrome P450 3A and P-glycoprotein. Carbamazepine 29-42 ATP binding cassette subfamily B member 1 Homo sapiens 89-103 24406279-5 2014 On the other hand, in order to explain the differences in the clinical response to CBZ, genetic polymorphisms in phase I (CYP3A4, CYP3A5 and EPHX1) and phase II (UGT2B7) metabolising enzymes have been assessed; additionally, the influence of transporters (ABCB1 and ABCC2), receptors (PXR) and other drug targets (voltage- gated Na+ channels) in CBZ clinical response has been evaluated. Carbamazepine 83-86 ATP binding cassette subfamily B member 1 Homo sapiens 256-261 24477677-11 2014 Of the various AEDs examined, only carbamazepine (100 muM) moderately increased Pgp functionality in hCMEC/D3, while valproate (300 muM) inhibited Pgp. Carbamazepine 35-48 ATP binding cassette subfamily B member 1 Homo sapiens 80-83 23717663-0 2013 Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital. Carbamazepine 159-172 ATP binding cassette subfamily B member 1 Homo sapiens 48-53 25495409-2 2014 MATERIALS & METHODS: For 210 epileptic patients treated with CBZ as monotherapy, nine SNPs in candidate genes ABCB1, CYP3A4, CYP3A5, POR and EPHX1 were analyzed by PCR-RFLP or direct sequencing. Carbamazepine 65-68 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 25495409-5 2014 RESULTS: The ABCB1 c.3435C>T was significantly associated with the CDR of CBZ and its major metabolites. Carbamazepine 77-80 ATP binding cassette subfamily B member 1 Homo sapiens 13-18 24338387-3 2013 We examined a possible relationship between patients" response to CBZ mono-therapy and the G2677T SNP of the ABCB1 gene. Carbamazepine 66-69 ATP binding cassette subfamily B member 1 Homo sapiens 109-114 23717663-3 2013 CBZ is transported by the P-glycoprotein (P-gp). Carbamazepine 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 26-40 23717663-3 2013 CBZ is transported by the P-glycoprotein (P-gp). Carbamazepine 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 42-46 23717663-6 2013 Our study is aimed at determining the correlation between patients" response to CBZ mono-therapy to Single Nucleotide Polymorphisms G2677T and C3435T of the ABCB1 gene as well as G1249A and -24C>T of the ABCC2 gene. Carbamazepine 80-83 ATP binding cassette subfamily B member 1 Homo sapiens 157-162 21530324-4 2011 The purpose of this study was to investigate a possible link between ABCB1 rs3789243 C>T, C1236T, G2677T/A, rs6949448 C>T, and C3435T haplotypes with response to carbamazepine (CBZ) or sodium valproate (VPA) monotherapy in Malaysian epilepsy patients. Carbamazepine 168-181 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 23252947-2 2013 MATERIALS & METHODS: Twenty-five SNPs within seven CBZ pathway genes, namely CYP3A4, CYP3A5, EPHX1, NR1I2, UGT2B7, ABCB1 and ABCC2, were analyzed for association with CBZ pharmacokinetics in 90 epilepsy patients. Carbamazepine 171-174 ATP binding cassette subfamily B member 1 Homo sapiens 119-124 23252947-5 2013 Among drug transporters, ABCB1 and ABCC2 SNPs were significantly associated with altered CBZ clearance. Carbamazepine 89-92 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 22188362-0 2012 Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Carbamazepine 88-101 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 21692796-0 2011 In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Carbamazepine 30-43 ATP binding cassette subfamily B member 1 Homo sapiens 123-137 21692796-5 2011 The objective of this study was to evaluate whether analogs and metabolites of the AED carbamazepine are substrates of human Pgp. Carbamazepine 87-100 ATP binding cassette subfamily B member 1 Homo sapiens 125-128 21692796-13 2011 SIGNIFICANCE: All carbamazepine analogs or metabolites tested are Pgp substrates, except for carbamazepine. Carbamazepine 18-31 ATP binding cassette subfamily B member 1 Homo sapiens 66-69 21692796-14 2011 These data suggest that resistance to carbamazepine, oxcarbazepine, or eslicarbazepine acetate may be attributed to increased efflux function of Pgp because they or their active metabolites are Pgp substrates. Carbamazepine 38-51 ATP binding cassette subfamily B member 1 Homo sapiens 145-148 21692796-14 2011 These data suggest that resistance to carbamazepine, oxcarbazepine, or eslicarbazepine acetate may be attributed to increased efflux function of Pgp because they or their active metabolites are Pgp substrates. Carbamazepine 38-51 ATP binding cassette subfamily B member 1 Homo sapiens 194-197 23252947-2 2013 MATERIALS & METHODS: Twenty-five SNPs within seven CBZ pathway genes, namely CYP3A4, CYP3A5, EPHX1, NR1I2, UGT2B7, ABCB1 and ABCC2, were analyzed for association with CBZ pharmacokinetics in 90 epilepsy patients. Carbamazepine 55-58 ATP binding cassette subfamily B member 1 Homo sapiens 119-124 21950458-1 2012 AIM: This aim of this study was to characterize the impact of the P-glycoprotein (P-gp) inducer, carbamazepine, on fexofenadine enantiomer pharmacokinetics. Carbamazepine 97-110 ATP binding cassette subfamily B member 1 Homo sapiens 66-80 21950458-1 2012 AIM: This aim of this study was to characterize the impact of the P-glycoprotein (P-gp) inducer, carbamazepine, on fexofenadine enantiomer pharmacokinetics. Carbamazepine 97-110 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 21530324-4 2011 The purpose of this study was to investigate a possible link between ABCB1 rs3789243 C>T, C1236T, G2677T/A, rs6949448 C>T, and C3435T haplotypes with response to carbamazepine (CBZ) or sodium valproate (VPA) monotherapy in Malaysian epilepsy patients. Carbamazepine 183-186 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 19206053-6 2009 Inducers of metabolism (rifampicin, carbamazepine, St. John"s Wort) also induce the expression of drug transporters like ABCB1. Carbamazepine 36-49 ATP binding cassette subfamily B member 1 Homo sapiens 121-126 20417680-3 2010 The aim of the present study was to investigate the role of ABCB1 polymorphisms: C1236T, G2677T/A and C3435T in determining drug response to first line antiepileptic drugs (AEDs) namely phenobarbitone, phenytoin, carbamazepine and valproate in North Indian cohort of epilepsy patients. Carbamazepine 213-226 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 21316268-7 2011 The aim of this study was to assess the association of ABCB1 and PXR genetic polymorphisms with response to the carbamazepine (CBZ) or sodium valproate (VPA) monotherapy in epilepsy. Carbamazepine 112-125 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 21316268-7 2011 The aim of this study was to assess the association of ABCB1 and PXR genetic polymorphisms with response to the carbamazepine (CBZ) or sodium valproate (VPA) monotherapy in epilepsy. Carbamazepine 127-130 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 21493161-0 2011 Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Carbamazepine 41-54 ATP binding cassette subfamily B member 1 Homo sapiens 11-16 21493161-2 2011 We sought to investigate the effects of ABCB1 polymorphisms on plasma carbamazepine (CBZ) concentrations and pharmacoresistance in Chinese patients with epilepsy. Carbamazepine 70-83 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 21493161-2 2011 We sought to investigate the effects of ABCB1 polymorphisms on plasma carbamazepine (CBZ) concentrations and pharmacoresistance in Chinese patients with epilepsy. Carbamazepine 85-88 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 21493161-3 2011 C1236T, G2677T/A, and C3435T polymorphisms of ABCB1 were genotyped by polymerase chain reaction amplification followed by restriction fragment length polymorphism analysis or direct automated DNA sequencing in 84 patients treated with CBZ monotherapy. Carbamazepine 235-238 ATP binding cassette subfamily B member 1 Homo sapiens 46-51 21493161-6 2011 Our results suggest that ABCB1 3435-TT is associated with decreased plasma CBZ levels in Chinese patients with epilepsy. Carbamazepine 75-78 ATP binding cassette subfamily B member 1 Homo sapiens 25-30 19934718-10 2009 In addition, when discontinuing carbamazepine in patients who are being concomitantly treated with a second-generation antipsychotic that is a CYP3A4/p-glycoprotein substrate, providers should arrange for patient follow-up 2-4 weeks after carbamazepine discontinuation to evaluate patients for antipsychotic-related adverse drug reactions. Carbamazepine 32-45 ATP binding cassette subfamily B member 1 Homo sapiens 150-164 17917461-0 2008 Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Carbamazepine 60-73 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 17917461-1 2008 BACKGROUND AND AIMS: We investigated the prevalence of this multidrug resistance 1 gene (MDR1) polymorphism in drug-responsive versus drug-resistant epilepsy patients treated with carbamazepine (CBZ), which is a substrate of this protein. Carbamazepine 180-193 ATP binding cassette subfamily B member 1 Homo sapiens 60-82 17917461-1 2008 BACKGROUND AND AIMS: We investigated the prevalence of this multidrug resistance 1 gene (MDR1) polymorphism in drug-responsive versus drug-resistant epilepsy patients treated with carbamazepine (CBZ), which is a substrate of this protein. Carbamazepine 180-193 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 17917461-1 2008 BACKGROUND AND AIMS: We investigated the prevalence of this multidrug resistance 1 gene (MDR1) polymorphism in drug-responsive versus drug-resistant epilepsy patients treated with carbamazepine (CBZ), which is a substrate of this protein. Carbamazepine 195-198 ATP binding cassette subfamily B member 1 Homo sapiens 60-82 17917461-1 2008 BACKGROUND AND AIMS: We investigated the prevalence of this multidrug resistance 1 gene (MDR1) polymorphism in drug-responsive versus drug-resistant epilepsy patients treated with carbamazepine (CBZ), which is a substrate of this protein. Carbamazepine 195-198 ATP binding cassette subfamily B member 1 Homo sapiens 89-93 17917461-2 2008 METHODS: We genotyped the C3435T variant of MDR1 in 97 patients treated with CBZ monotherapy who had been on stable doses for more than 1 month. Carbamazepine 77-80 ATP binding cassette subfamily B member 1 Homo sapiens 44-48 16842400-0 2006 Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Carbamazepine 46-59 ATP binding cassette subfamily B member 1 Homo sapiens 13-27 16842400-3 2006 In this study, we have investigated whether CBZ acts as an inducer of Pgp in lymphocytes. Carbamazepine 44-47 ATP binding cassette subfamily B member 1 Homo sapiens 70-73 16842400-4 2006 METHODS: Pgp expression was assessed by flow cytometry and real-time reverse transcriptase-polymerase chain reaction using lymphocytes from four healthy subjects after incubation with therapeutic concentrations of CBZ, using rifampicin as a positive control. Carbamazepine 214-217 ATP binding cassette subfamily B member 1 Homo sapiens 9-12 16842400-11 2006 CONCLUSIONS: Carbamazepine induces Pgp in a manner comparable to rifampicin, by increasing binding to the DR4 element. Carbamazepine 13-26 ATP binding cassette subfamily B member 1 Homo sapiens 35-38 17971810-1 2008 The aim of this study was to develop a model describing the carbamazepine autoinduction and the carbamazepine-mediated induction of CYP3A4, CYP1A2, and P-glycoprotein. Carbamazepine 96-109 ATP binding cassette subfamily B member 1 Homo sapiens 152-166 17376120-5 2007 RESULTS: Low carbamazepine plasma levels showed a trend towards higher intestinal MDR1 expression (P = 0.06). Carbamazepine 13-26 ATP binding cassette subfamily B member 1 Homo sapiens 82-86 17376120-7 2007 Moreover, MDR1 expression and carbamazepine and phenytoin dose requirement was influenced by the genotype in position 2677 and 3435 of the MDR1 gene. Carbamazepine 30-43 ATP binding cassette subfamily B member 1 Homo sapiens 139-143 17376120-8 2007 CONCLUSION: Differences in intestinal MDR1 and MRP2 expression may influence carbamazepine and phenytoin disposition and may account for interindividual pharmacokinetic variability. Carbamazepine 77-90 ATP binding cassette subfamily B member 1 Homo sapiens 38-42 16753003-2 2006 Our objective was to investigate the effect of ABCB1 polymorphisms on AED responsiveness and on the pharmacokinetics of carbamazepine (CBZ) in epileptic patients with the indication for CBZ therapy. Carbamazepine 120-133 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 16753003-2 2006 Our objective was to investigate the effect of ABCB1 polymorphisms on AED responsiveness and on the pharmacokinetics of carbamazepine (CBZ) in epileptic patients with the indication for CBZ therapy. Carbamazepine 186-189 ATP binding cassette subfamily B member 1 Homo sapiens 47-52 16753003-7 2006 CBZ concentrations to the dose (C/D) ratios were compared among the ABCB1 polymorphisms. Carbamazepine 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 68-73